Enhancing gut microbiota reduces spinal cord injury pneumonia risk via gut-lung interactions

Research Hypothesis: Our research hypothesis was that enhancing the gut microbiota after spinal cord injury (SCI) could reduce the risk of pneumonia by modulating the gut-lung axis. We posited that probiotic supplementation could rebalance gut microbiota, thereby mitigating lung microbiota dysbiosis and decreasing the incidence of pneumonia in SCI patients. Data Collection and Analysis: To test our hypothesis, we conducted a series of controlled experiments using both human and mouse models. For the human study, we collected data from patients with SCI at Huashan Hospital, tracking incidences of pneumonia and analyzing gut and lung microbiota compositions through high-throughput sequencing of bacterial 16S rRNA genes. In our mouse model, SCI was surgically induced, followed by administration of specific probiotics. We monitored changes in the microbiota, the occurrence of pneumonia, and immune responses over time. Notable Findings: Gut-Lung Microbiota Similarity: Post-SCI, there was a significant increase in the similarity between gut and lung microbiota in both humans and mice, suggesting potential microbial translocation between these sites. Probiotic Supplementation: Supplementation with Bifidobacterium and Akkermansia in mice led to a marked improvement in the diversity and stability of gut microbiota. This change was associated with reduced lung microbiota dysbiosis and lower inflammation levels in the lungs. Reduction in Pneumonia Incidence: In the human cohort, SCI patients who received probiotic supplementation showed a statistically significant reduction in pneumonia incidence compared to those who did not receive probiotics. Interpretation of Data: The data supports the hypothesis that gut microbiota modulation has a protective effect against pneumonia post-SCI, likely mediated through the gut-lung axis. The observed increase in microbiota similarity between the gut and lungs post-SCI suggests that microbial translocation could be a contributing factor to lung infections. Probiotic supplementation appears to stabilize gut microbiota, which in turn may help to maintain lung microbiota balance and immune function, thereby reducing the risk of pneumonia. Usage of Data: This data can be utilized to further explore the therapeutic potential of targeting the gut microbiota in SCI patients to prevent secondary infections such as pneumonia. The findings also suggest broader applications in managing pulmonary infections by modulating gut microbiota in other patient populations susceptible to dysbiosis and immune suppression. Further research should investigate the specific mechanisms of microbial translocation and the role of individual microbial species in promoting lung health post-injury.

研究假设：本研究提出核心假设，即脊髓损伤（spinal cord injury, SCI）后通过调控肠-肺轴（gut-lung axis）改善肠道菌群稳态，可降低肺炎发生风险。我们推测，益生菌补充干预可重建肠道菌群平衡，进而缓解肺部菌群失调，降低脊髓损伤患者的肺炎发病率。
数据收集与分析：为验证上述假设，本研究采用人与小鼠模型开展一系列对照实验。人体研究部分，我们于华山医院收集脊髓损伤患者的临床数据，追踪其肺炎发生情况，并通过细菌16S rRNA基因高通量测序技术分析肠道与肺部菌群的组成结构。小鼠模型实验中，我们通过外科手段构建脊髓损伤模型，随后给予特定益生菌干预，动态监测菌群变化、肺炎发生情况以及免疫应答随时间的改变。
核心研究发现：肠-肺菌群相似性：脊髓损伤后，人体与小鼠模型的肠道与肺部菌群相似性均显著升高，提示二者之间存在潜在的微生物移位现象。益生菌补充的改善效果：给小鼠补充双歧杆菌（Bifidobacterium）与嗜黏蛋白阿克曼菌（Akkermansia）后，其肠道菌群的多样性与稳定性均得到显著提升，该变化与肺部菌群失调程度减轻、肺部炎症水平降低显著相关。肺炎发生率降低：在人体队列中，接受益生菌补充的脊髓损伤患者，其肺炎发生率较未补充益生菌的患者呈现统计学意义上的显著下降。
数据解读：本研究数据支持前述假设，即调控肠道菌群可对脊髓损伤后肺炎发挥保护作用，其潜在机制可能通过肠-肺轴介导。脊髓损伤后肠道与肺部菌群相似性升高的现象，提示微生物移位可能是肺部感染的潜在诱因之一。益生菌补充可稳定肠道菌群结构，进而有助于维持肺部菌群平衡与免疫功能，最终降低肺炎发生风险。
数据集应用价值：本数据集可用于进一步探索靶向脊髓损伤患者肠道菌群的治疗潜力，以预防肺炎等继发感染。本研究发现还提示，对于其他存在菌群失调与免疫抑制风险的患者群体，通过调控肠道菌群管理肺部感染或具有更广泛的应用前景。未来研究可进一步探究微生物移位的具体机制，以及单一微生物物种在损伤后肺部健康维护中的作用。